|
Comparison of definitive cervical cancer management with concurrent chemotherapy and radiation between two centers with variable resources and opportunities for improved treatment delivery. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Daniel Celestino Fernandez |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Ovation Diagnostics |
|
Consulting or Advisory Role - Clovis Oncology; Genentech; Merck; Mersana; Tesaro |
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro |
Research Funding - Merck (Inst); Prescient Therapeutics (Inst) |
Travel, Accommodations, Expenses - TapImmune Inc. |
|
|
No Relationships to Disclose |
|
|
|
Speakers' Bureau - Johnson & Johnson |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb; Genentech/Roche |